ASK REDCHAT ANYTHING ABOUT NUCANA PLC
NuCana plc (NASDAQ: NCNA)
Listen to this Section
$1.67
+0.0250
(
+1.52% )
23.3K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| NUC-7738 (ProTide) +/- pembrolizumabDetailsSolid tumor/s, Cancer, Melanoma |
Phase 2 |
| NUC-3373 (ProTide) combo w/ pembrolizumabDetailsSolid tumor/s, Cancer, Lung cancer |
Phase 1b |
| NUC-3373 (ProTide) combo w/ irinotecan/bevacizumab/oxaliplatinDetailsColorectal cancer , Cancer |
Failed |
| Acelarin (NUC-1031) (dFdCTP)DetailsCancer, Biliary Tract Cancer |
Failed |
Market Data
|
| Open |
$1.67 |
| Previous Close |
$1.64 |
| Volume |
23.3K |
| Market Cap |
$6.83M |
| Day Range |
$1.57 - $1.70 |
| 52 Week Range |
$1.33 - $25.58 |
| Shares Outstanding |
4.16M |
| Change % |
+1.52% |
| Net Change |
▲ 0.0250 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2017 |
| Country | United Kingdom |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 6-k |
Form 6-K |
4 |
Nov 13, 2025 |
| 6-k |
Form 6-K |
2 |
Nov 05, 2025 |
| 6-k |
Form 6-K |
2 |
Oct 20, 2025 |
| 6-k |
Form 6-K |
2 |
Oct 14, 2025 |
| 6-k |
Form 6-K |
2 |
Sep 05, 2025 |
| 6-k |
Form 6-K |
2 |
Sep 03, 2025 |
| 6-k |
Form 6-K |
57 |
Aug 20, 2025 |
| 6-k |
Form 6-K |
2 |
Aug 01, 2025 |
| 6-k |
Form 6-K |
2 |
Jul 21, 2025 |
| 6-k |
Form 6-K |
2 |
Jul 11, 2025 |